Consensus Conference

Defining Pathways for Development of Disease Modifying Therapies in Children with Type 1 Diabetes

Co-Chairs: Carla Greenbaum, MD and Diane Wherrett, MD, FRCP(C)

STATEMENT OF NEED
Despite medical advances, type 1 diabetes (T1D) remains a significant burden on individuals with T1D and their families; thus there is need for disease modifying therapy. While autoimmune diabetes occurs in all age groups, emerging data highlights important differences in pathophysiology and clinical course according to age at diagnosis. Consequently, the effectiveness of disease modifying treatments is expected to be different between children and adults. Understanding the development and regulatory pathways for T1D disease modifying therapies according to age will enable industry, academia, funders, advocacy organizations, and regulators to collectively translate new science to clinical care.

OBJECTIVES
The objectives for this Consensus Conference are to characterize the fundamental differences in T1D between children and adults and to propose a thoughtful approach for developing disease modifying therapeutics in children before or after the onset of clinical T1D; encompassing a development and regulatory pathway considering both safety and efficacy. It is the intent that the Consensus Conference Report will be published in Diabetes Care and notable pediatric journals.

WHEN:
January 14, 2015
8:30 am - 4 pm EST

LOCATION:
Hilton Mark Center
5000 Seminary Road
Alexandria, VA 22311

OPEN REGISTRATION:
To register, please contact Sonya Pendleton at spendleton@diabetes.org or 703.549.1500 ext. 2311 by December 15, 2014.

Registration Fee: $75.00

SPONSORED BY

IN COLLABORATION WITH
Defining Pathways for Development of Disease Modifying Therapies in Children with Type 1 Diabetes
CONSSENSUS CONFERENCE AGENDA
January 14, 2015

All presentations will be 20 minutes, followed by 10 minutes for discussion

7:30-8:15 am  Breakfast

8:15-8:30  Welcome & Meeting Objectives
  Diane Wherrett, MD

8:30-9:00  Current metabolic control in children and adults
  Linda DiMeglio, MD

9:00-9:30  History of disease modifying therapy trials in children
  Des Schatz, MD/Jay Skyler MD

9:30-10:00  Complications; morbidity/mortality in those diagnosed as children
  Trevor Orchard, MD

10:00-10:15  Break

10:15-11:15  Differences between pediatric and adult onset T1D
  Pathophysiology pre-diagnosis  Peter Gottlieb, MD
  C-peptide post diagnosis  Stephen Gitelman, MD

11:15-11:45  Quality of Life in T1D in those diagnosed as children
  Alan Delamater PhD

11:45-12:15  Cognitive effects of diabetes in childhood
  Christopher Ryan, PhD

12:15-1:00  Lunch

1:00-1:30  Lessons from other diseases (pediatric rheumatology)
  Daniel Lovell, MD
1:30-2:00  European Medicines Agency  
Paolo Tomasi, MD

2:00-2:30  Food and Drug Administration  
Dianne Murphy, MD

2:30-3:00  Risk/benefit; ethical issues in studying children  
David Wendler, MD

3:00-3:30  Panel Discussion  
TBD

3:30-4:00  Summary of meeting discussion including:  
Meeting summary  
Unmet needs  
Areas of future research  
Carla Greenbaum, MD